Exact Sciences recently announced its fourth quarter numbers, which included revenues between $142.5 million – $143.5 million and 292,000 completed Cologuard tests, an increase of 64 percent and 66 percent from last year, respectively.

“2018 was a landmark year for Exact Sciences,” Exact Sciences CEO Kevin Conroy said in a statement. “We helped more than 930,000 people get screened for colorectal cancer, launched a partnership with Pfizer to help bring Cologuard to more patients, and scaled our operations to meet rising demand. In 2019, we expect to open a new clinical lab, integrate Epic software into our operations and advance our pipeline of liquid biopsy tests.”

According to a release, for the entire 2018 year, Exact Sciences expects revenues between $454 million and $455 million and 934,000 completed Cologuard tests.

These are the preliminary results, as Exact Sciences said it will release its final 2018 financial results in February.